KONEXBiotech & Pharma456570

IMGT

₩9,780▼ 1.91%2026-11-18 close
Market Cap
₩51.5B
Turnover
₩10,426,230
Volume
1.1K
Shares out.
5.3M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Clinical-stage drug delivery under capital impairment

Beyond a KRW 5.6 billion operating loss, capital impairment, funding, and clinical progress are the core variables for IMGT.

  1. 1

    Based on 2025 reported results, the operating loss was KRW 5.6 billion and the net loss widened to KRW 40 billion.

  2. 2

    Total equity stood at KRW -60.2 billion, leaving the company in a state of capital impairment.

  3. 3

    The FDA Breakthrough Device designation and the multinational, multicenter pancreatic cancer trial are the key business variables.

  4. 4

    Revenue remains minimal, and no commercialization timeline has been confirmed.

  5. 5

    At the March 2026 annual general meeting, shareholders approved the financial statements and a stock option grant.

02

Business structure

IMGT, founded in April 2010 and listed on KONEX, develops focused-ultrasound (FUS) systems that deliver anticancer drugs efficiently to tumor sites. Its business report describes the development and sale of image-guided drug delivery systems as its main business.

The core product is IMD10, a focused-ultrasound system for anticancer drug delivery aimed at raising the absorption of pancreatic cancer drugs in the body. A second pipeline asset, IMP101, is positioned as a drug carrier that extends the residence time of liver-treatment drugs.

The revenue profile still resembles a research-stage company rather than a product seller, with 2024 revenue reported at roughly KRW 30 million. In 2025 the company received FDA Breakthrough Device designation for a pancreatic cancer indication and is running a multinational, multicenter clinical study.

According to the company summary, an exploratory trial at Seoul National University Hospital confirmed the safety and efficacy of combining an anticancer drug with focused ultrasound. Because the trial is exploratory and small, it should be read differently from a confirmatory study.

Unlike drugmakers that develop their own drug candidates, IMGT is positioned as a platform company that improves the delivery efficiency of existing anticancer drugs, which invites comparison with Peptron, another listed biopharma that centers its business on delivery technology.

A securities firm analysis cites a cost ratio of about 10% and localization of core components as grounds for possible technology export and mass-production royalty revenue.

However, no commercial sales ramp or technology transfer contract has been confirmed, so the business still depends on clinical progress and funding.

03

Recent trends

Based on 2025 reported results, the operating loss was KRW 5.6 billion, roughly unchanged from the prior year on a consolidated basis. The net loss widened to KRW 40 billion, an increase of 228.4% from the prior year.

At the end of 2025, total equity was KRW -60.2 billion, total liabilities KRW 75.3 billion, and total assets KRW 15.1 billion, so liabilities far exceed assets. The current ratio stood at 24.5% for 2025.

Shares outstanding rose from 4,815 thousand in 2023 to 5,256 thousand in 2025, and the 2025 loss per share was KRW 5,092.

Reports on 2024 differ: NICE D&B financial data put 2024 revenue at KRW 30 million and net loss at KRW 11.24 billion, while a press report cited an operating loss of about KRW 5.44 billion and a net loss of about KRW 11.23 billion for the same year.

According to recent press reports, the March 31, 2026 annual general meeting approved the financial statements, the remuneration limit, and a stock option grant. The same reports said 130,220 common shares were granted to 31 employees and directors, with a fair value of KRW 4,611 per share.

As of November 11, 2026, the share price was KRW 10,770, down 3.84% from the prior session, with a market capitalization of KRW 56.7 billion. The 52-week range observed at the time of the query was KRW 8,690 to KRW 28,000.

04

Outlook

Future developments can be organized around three axes. The first is funding: with total equity at KRW -60.2 billion and liabilities at KRW 75.3 billion, the company has relied on third-party share placements and convertible redeemable preferred share issuance to secure operating capital.

The second is clinical progress: the multinational, multicenter pancreatic cancer study and follow-up steps after the FDA Breakthrough Device designation are central to how the business is assessed. Whether the exploratory trial results hold in larger studies is the key checkpoint.

The third is commercialization structure: the cost ratio and localization strategy are presented as preconditions for technology export and royalty revenue, but the timing and size of any commercial sales or contracts have not been confirmed.

The KONEX listing is also a factor, since thin trading volume tends to make the share price sensitive to individual disclosures and funding news. A possible KOSDAQ transfer listing cited by a securities analyst remains a forecast, and an actual transfer depends on exchange procedures and eligibility.

05

Bull factors

FDA designation and clinical progress

The 2025 FDA Breakthrough Device designation for a pancreatic cancer indication can be read as external recognition of the technology's direction.

According to the company summary, an exploratory trial at Seoul National University Hospital reported a maximum target-lesion size change of 1.8 times and an objective response rate of 60%. The same summary also cites a hazard ratio of 0.44 and a median survival extension of 5.1 months.

Because these are exploratory results, whether they replicate in later trials is the point that determines how strong this factor is.

Low cost ratio and pipeline expansion

According to a securities firm analysis, the cost ratio is only about 10%, and localization of core components is expected to strengthen competitiveness. The technology extends from an anticancer device to the liver-treatment drug carrier IMP101, giving the platform more than one application. If technology export or mass-production royalties materialize, this structure could alter the revenue profile.

Funding channels and incentive structure

To secure operating funds, the company has decided on third-party share placements and convertible redeemable preferred share issuance, which provide financing channels. At the March 2026 annual general meeting, shareholders approved the financial statements and a stock option grant.

According to recent press reports, 130,220 common shares were granted to 31 employees and directors, with a fair value of KRW 4,611 per share, which links employee compensation to shareholder value.

06

Bear factors

Capital impairment and debt burden

At the end of 2025, total equity was KRW -60.2 billion and total liabilities were KRW 75.3 billion, far above total assets of KRW 15.1 billion. The current ratio stood at a low 24.5% for 2025. The net loss widened to KRW 40 billion, up 228.4% from the prior year.

While capital impairment persists, the structure keeps requiring additional external funding, which is the core bearish factor.

Revenue gap and uncertain commercialization timing

Revenue in 2024 was reported at roughly KRW 30 million, and no sustained commercial product sales have been confirmed. Although the 2025 operating loss of KRW 5.6 billion is relatively modest, continued clinical and R&D work raises funding needs. Without a clear approval and sales timetable, the timing of monetization is difficult to estimate.

Share price volatility and KONEX liquidity

As of November 11, 2026, the share price was KRW 10,770, down 3.84% from the prior session, with a market capitalization of KRW 56.7 billion. The 52-week range observed at the time of the query spans KRW 8,690 to KRW 28,000, a wide band.

Shares outstanding rose from 4,815 thousand in 2023 to 5,256 thousand in 2025, so funding has translated into a larger share count. Thin KONEX trading also tends to amplify price moves.

07

Risk factors

Macro

Interest rate levels and risk appetite in Korean equities shape the funding conditions for small biotech companies. KONEX trading volumes are small relative to KOSPI and KOSDAQ, so broader sentiment declines can weigh on the share price more heavily. Rates and investor sentiment at the time of any share issuance affect financing terms and dilution.

Regulatory and clinical

If exploratory results do not replicate in larger trials, indication expansion and technology transfer discussions could be delayed. Treatments that combine drugs with devices face multi-path approval routes, which can add regulatory requirements.

Breakthrough Device designation does not guarantee market approval, and that distinction matters for any assessment of the business.

Financing and ownership

With total equity negative, the choice among share placements, convertible preferred shares, and borrowing determines how much existing shareholders are diluted.

A past press report put the stake held by the representative director and related parties at 33.41%, which, together with limited free float, can influence price volatility. Convertible redeemable preferred shares could convert into common shares, so the path of share count changes needs to be tracked.

08

Overall view

IMGT combines a differentiated focused-ultrasound drug delivery platform with an external recognition in the form of FDA Breakthrough Device designation.

On the other hand, total equity of KRW -60.2 billion, liabilities of KRW 75.3 billion, and a net loss of KRW 40 billion at the end of 2025 show a weak financial position. With almost no revenue, the business value depends heavily on clinical results and funding capacity.

A securities firm emphasizes the low cost ratio and possible technology export, but these have not been confirmed through contracts or sales. The exploratory trial figures are encouraging, yet their sample size and design limits mean they should be read separately from larger trial results.

As of November 11, 2026, the share price was KRW 10,770, within a wide 52-week range, and KONEX trading liquidity is limited. This report offers no investment opinion and aims to organize business progress and balance sheet changes on a factual basis.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 8 more articles and sources
  1. comp.fnguide.com
  2. thevc.kr
  3. prestocknews.com
  4. m.news.nate.com
  5. investing.com
  6. kind.krx.co.kr
  7. lab.incruit.com
  8. kr.investing.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis